

Connecticut Department of Social Services Medical Assistance Program

www.ctdssmap.com

Provider Bulletin 2021-28 April 2021

TO: Pharmacy Providers, Physicians, Nurse Practitioners, Physician Assistants, Clinics, Long Term Care Providers, and Hospitals

RE: New Prior Authorization Requirement for Evrysdi

Effective June 1, 2021, the Department of Social Services (DSS) will implement a Prior Authorization (PA) requirement for prescription benefit coverage of Risdiplam, marketed as Evrysdi TM, for HUSKY A, HUSKY B, HUSKY C, and HUSKY D.

The U.S Food and Drug Administration (FDA) has approved Risdiplam for the treatment of spinal muscular atrophy (SMA) in patients two (2) months of age and older. SMA is a hereditary disease that causes weakness and muscle wasting due to the loss of lower motor neurons responsible for controlling movement. Risdiplam is the first oral agent indicated for SMA.

Prior Authorization (PA) Requirements

Clinical criteria for PA approval for Rispaldam is as follows:

- 1. The patient must be age 2 months or older;
- 2. The patient must have a diagnosis of spinal muscular atrophy (SMA);
- 3. The patient is **NOT** receiving concomitant chronic survival motor neuron (SMN) modifying therapy, i.e. Spinraza TM (nusinersen);
- 4. The patient has a documented decline in functional status related to SMA (i.e. loss of motor milestone(s)) in patients who have previously received gene replacement therapy with ZolgensmaTM (onasemnogene abeparvovci-xioi).

In instances where the individual does not meet these criteria, the prescriber must write a letter of medical necessity to DSS' Medical Director for consideration. Letters of medical necessity can be emailed with the Evrysdi PA form to Rx.LMN@ct.gov.

The new Evrysdi PA Form is attached below and will be available on the www.ctdssmap.com Web site. From the Home page, go to Information > Publications > Authorization/Certification Forms > Evrysdi PA Form; or from the Home page, go to Pharmacy Information > Pharmacy Program Publications > Evrysdi PA Form.



STATE OF CONNECTICUT DEPARTMENT OF SOCIAL SERVICES PO BOX 2943 HARTFORD, CT 06104

TELEPHONE: 1-866-409-8386 FAX: 1-866-759-4110 OR (860) 269-2035

Letters of Medical Necessity: Rx.LMN@CT.GOV

CT Medical Assistance Program EvrysdiTM (risdiplam) Authorization (PA) Request Form [This and other pharmacy PA forms are available at www.ctdssmap.com]

To Be Completed By Prescriber

Prescriber Information	Patient Information		
Prescriber Name:	Client Name:		
Prescriber's NPI:	Client ID Number:		
Phone # ()	Patient DOB: / /		
Fax # ()	Primary ICD diagnosis code:		
Prescri	ption Information		
Drug Requested:	Dose/frequency:		
	Expected Duration:		
ammorizanon win de given for twelve ((12) months only. The provider listed in		
agrees to monitor the patient over the discontinue this medication in the even	nt a positive response is not observed. answered with <u>"No",</u> a Letter of Medic	eal Neces	ssity must
agrees to monitor the patient over the discontinue this medication in the even ***If <u>ANY</u> of the questions below are submitted to the Department of Social	nt a positive response is not observed. answered with "No", a Letter of Medic Services via email @ Rx.lmn@ct.gov f	eal Neces	ssity must
agrees to monitor the patient over the discontinue this medication in the even	nt a positive response is not observed. answered with "No", a Letter of Medic Services via email @ Rx.lmn@ct.gov f	al Neces	ssity must deration.
***If ANY of the questions below are submitted to the Department of Social Is the patient the age of two (2) months or older Does patient have a diagnosis of spinal muscular	nt a positive response is not observed. answered with "No", a Letter of Medic Services via email @ Rx.lmn@ct.gov f	cal Neces for consi	ssity must
***If ANY of the questions below are submitted to the Department of Social Is the patient the age of two (2) months or older Does patient have a diagnosis of spinal muscular The patient is NOT receiving concomitant characteristics. SPINRAZA® (nusinersen)? If patient has previously received gene	answered with "No", a Letter of Medic Services via email @ Rx.lmn@ct.gov for? ar atrophy (SMA)?	al Neces for consi	ssity must deration.
***If ANY of the questions below are submitted to the Department of Social Is the patient the age of two (2) months or older Does patient have a diagnosis of spinal muscular The patient is NOT receiving concomitant characteristics, SPINRAZA® (nusinersen)? If patient has previously received gene (onasemnogene abeparvovci-xioi), has there be milestone(s))?	answered with "No", a Letter of Medic Services via email @ Rx.lmn@ct.gov f ar atrophy (SMA)? ronic survival motor neuron (SMN) modifying replacement therapy with ZOLGENSMA®	□ Yes □ Yes □ Yes □ Yes	ssity must deration. No No No No

This form (and attachments) contains protected health information (PHI) for Gainwell Technologies and is covered by the Electronic Communications Privacy Act, 18 U.S.C. §2510-2521 and the Standards for Privacy of Individually Identifiable Health Information, 45 CFR Parts 160 and 164, which is intended only for the use of prior authorization. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited. Any unintended recipient should contact Gainwell Technologies by telephone at (860) 255-3900 or by e-mail immediately and destroy the original message.